Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 10

Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy

Authors Goldschmidt CH, Hua LH

Received 19 March 2020

Accepted for publication 10 June 2020

Published 26 June 2020 Volume 2020:10 Pages 29—38

DOI https://doi.org/10.2147/DNND.S224912

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Thomas Müller


Carolyn H Goldschmidt,1 Le H Hua2

1Cleveland Clinic Mellen Center for the Treatment of Multiple Sclerosis, Cleveland, OH, USA; 2Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Correspondence: Le H Hua
Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W. Bonneville Ave, Las Vegas, NV 89106, USA
Tel +1 702-486-3000
Fax +1 702-778-7004
Email hual@ccf.org

Abstract: The advent of interferon therapy for the treatment of multiple sclerosis (MS) was a massive advancement in the field and changed the course of the disease. While the exact mechanism of interferon therapy in MS is unknown, disease control is likely mediated by reducing Th1 and Th17 cells while increasing regulatory T cells and altering the cytokine profile. Interferon therapy not only gave physicians and patients an evidence-based treatment option to treat MS by decreasing relapses and the accrual of disability but it also provided valuable insight into disease pathophysiology that allowed for the development of further treatments. Currently, there are 18 disease-modifying therapies available for the treatment of MS with varying efficacies, routes of administration, and mechanisms. As treatment options in the field have evolved, interferon therapy is less commonly prescribed as first-line therapy, because the newer therapies are more effective and better tolerated. That being said, interferons still have a place in the field in both clinical practice and clinical trial research. In this review, we will summarize the safety and efficacy of interferon therapy and discuss its current place in MS care.

Keywords: multiple sclerosis, interferon-beta therapy, disease-modifying therapy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]